Continuous monitoring of body chemistry is crucial for the management of chronic diseases such as diabetes, but blood draws and implanted sensor wires remain invasive, uncomfortable, and expensive for everyday use. The microneedle sensor is a micrometer-scale projection array that can penetrate the stratum corneum and the interstitial fluid (ISF) of the sample without touching the pain-sensing nerve endings, and it is a minimally invasive method for detecting subcutaneous biomarkers. This paper follows the thread that actually decides how such a device performs. The materials read like a trade-off table. Metal and silicon give dense, conductive arrays but stay rigid and pricey; polymers are cheap enough to throw away after use, yet bend; hydrogels load enzymes and dyes straight into the matrix, but respond slowly. The chemistry maps onto targets, not the other way around. Enzymatic amperometry still owns glucose and lactate; potentiometric membranes handle ions; aptamers and antibodies open the door to proteins and narrow-window drugs; fluorescent biodegradable patches let a smartphone read through the skin with nothing left behind. Building on these schemes, integrated patches now measure two metabolites at once in volunteers, dual glucose-and-metformin platforms report pharmacokinetic and pharmacodynamic feedback in diabetic animals, and disposable cartridges separate cheap consumables from reusable electronics. The remaining barrier is no longer device chemistry but longitudinal patient-grade validation and regulatory standardization. Closing this gap could turn microneedle patches into everyday closed-loop tools for personalized disease management.
Research Article
Open Access